Highlights Newsletter 1 This newsletter presents you the following key sessions: Watch the video interview with professor Peter Schmid about the results of the phase III Impassion130 trial: clinically significant benefit in progression-free survival in patients with locally advanced or metastatic triple-negative breast cancer treated with atezolizumab + nab-paclitaxel Combining abiraterone acetate with radium-223 not recommended as first-line therapy for metastatic castration-resistant prostate cancer patients with bone metastases Improved progression-free survival of patients with HR+, HER2- advanced breast cancer treated with the PI3K inhibitor alpelisib Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC Gene expression profiles are associated with differential outcomes to atezolizumab plus bevacizumab or sunitinib as first-line treatment for metastatic renal cell carcinoma